Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo is dated May 5, 2004. The report addresses the ongoing regulatory review of the company's acquisition offer for Aventis by the U.S. Federal Trade Commission (FTC). The filing serves as an update on the Hart-Scott-Rodino (HSR) antitrust waiting period and the status of the proposed transaction.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is exclusively focused on regulatory and transactional updates regarding the Aventis acquisition.
Material Changes and Transaction Status
- FTC Second Request: On May 5, 2004, the FTC issued a "second request" for information to complete its investigation into the offer for Aventis. This is described as standard practice for transactions of this significance.
- HSR Waiting Period: The initial 30-day HSR waiting period, which began on April 5, 2004, expired on May 5, 2004. The issuance of the second request extends the regulatory review timeline.
- Divestiture Commitment: Sanofi-Synthelabo has agreed to divest Arixtra and Fraxiparine to GlaxoSmithKline to resolve FTC concerns, contingent on the success of the offer.
- Offer Terms: An increased offer for Aventis was announced on April 26, 2004, and recommended by the Aventis Supervisory Board. This offer is not subject to the condition precedent of the HSR waiting period expiration.
Guidance, Outlook, and Management Commentary
Management states that Sanofi-Synthelabo and Aventis will fully cooperate with the FTC to resolve remaining issues promptly. The company does not expect the FTC's second request to delay or affect the completion of the exchange offer, which is still expected to occur on or before the end of the second quarter of 2004. Furthermore, management asserts that the resolution of issues with the FTC will not have a material impact on the business of the future combined group.
Important Facts for Investor Verification
- Verify the timeline for the completion of the Aventis acquisition, specifically the expectation of closing by the end of Q2 2004 despite the FTC second request.
- Confirm the terms of the divestiture of Arixtra and Fraxiparine to GlaxoSmithKline as a condition for regulatory approval.
- Review the Registration Statement on Form F-4 (File No. 333-112314) and the related prospectus for detailed terms of the exchange offer.
- Monitor subsequent filings for updates on the FTC investigation and any potential changes to the closing date.